Resmed has its origins in the 1980s, when Sydney sleep expert Dr Colin Sullivan converted a vacuum cleaner to deal with the ...
They knew people who were taking Zepbound, Wegovy, Mounjaro, Ozempic. And so they piled in and the valuations, I mean, Eli Lilly is trading ... and that kind of masks for a while our understanding ...
Some analysts expect demand for ResMed's CPAP devices to be disrupted by the U.S. approval for Eli Lilly's weight-loss ... for its sleep devices and the masks portfolio. Analysts on average ...
David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous ...
It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...
Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...
In a recent press release, Eli Lilly's management said that the U.S. incretin market, which includes drugs like Zepbound and Mounjaro, didn't grow as fast as it anticipated in the fourth quarter.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback